1. Home
  2. VCEL vs OXLCO Comparison

VCEL vs OXLCO Comparison

Compare VCEL & OXLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VCEL
  • OXLCO
  • Stock Information
  • Founded
  • VCEL 1989
  • OXLCO N/A
  • Country
  • VCEL United States
  • OXLCO United States
  • Employees
  • VCEL N/A
  • OXLCO N/A
  • Industry
  • VCEL Biotechnology: Biological Products (No Diagnostic Substances)
  • OXLCO Investment Managers
  • Sector
  • VCEL Health Care
  • OXLCO Finance
  • Exchange
  • VCEL Nasdaq
  • OXLCO Nasdaq
  • Market Cap
  • VCEL 2.1B
  • OXLCO N/A
  • IPO Year
  • VCEL 1997
  • OXLCO N/A
  • Fundamental
  • Price
  • VCEL $40.25
  • OXLCO $23.24
  • Analyst Decision
  • VCEL Strong Buy
  • OXLCO
  • Analyst Count
  • VCEL 8
  • OXLCO 0
  • Target Price
  • VCEL $62.00
  • OXLCO N/A
  • AVG Volume (30 Days)
  • VCEL 477.0K
  • OXLCO N/A
  • Earning Date
  • VCEL 07-31-2025
  • OXLCO N/A
  • Dividend Yield
  • VCEL N/A
  • OXLCO N/A
  • EPS Growth
  • VCEL 521.85
  • OXLCO N/A
  • EPS
  • VCEL 0.05
  • OXLCO N/A
  • Revenue
  • VCEL $238,541,000.00
  • OXLCO N/A
  • Revenue This Year
  • VCEL $23.03
  • OXLCO N/A
  • Revenue Next Year
  • VCEL $24.52
  • OXLCO N/A
  • P/E Ratio
  • VCEL $780.58
  • OXLCO N/A
  • Revenue Growth
  • VCEL 14.80
  • OXLCO N/A
  • 52 Week Low
  • VCEL $37.39
  • OXLCO N/A
  • 52 Week High
  • VCEL $63.00
  • OXLCO N/A
  • Technical
  • Relative Strength Index (RSI)
  • VCEL 44.06
  • OXLCO 56.08
  • Support Level
  • VCEL $39.39
  • OXLCO $23.16
  • Resistance Level
  • VCEL $42.61
  • OXLCO $23.25
  • Average True Range (ATR)
  • VCEL 1.73
  • OXLCO 0.07
  • MACD
  • VCEL -0.15
  • OXLCO -0.00
  • Stochastic Oscillator
  • VCEL 24.16
  • OXLCO 61.11

About VCEL Vericel Corporation

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

About OXLCO Oxford Lane Capital Corp. Preferred Stock Shares 6.00% Series 2029

Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize its portfolio's risk-adjusted total return over its investment horizon. Its current focus is to seek that return by investing in equity and junior tranches of CLO(collateralized loan obligation) vehicles, which are collateralized by a diverse portfolio of senior loans, and which generally have little to no exposure to real estate loans, mortgage loans or pools of consumer-based debt, such as credit card receivables or auto loans. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.

Share on Social Networks: